Chapman Financial Group LLC Takes $1.17 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Chapman Financial Group LLC purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 10,972 shares of the medical equipment provider's stock, valued at approximately $1,171,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. CKW Financial Group increased its position in shares of Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock worth $101,000 after purchasing an additional 100 shares in the last quarter. Romano Brothers AND Company grew its holdings in shares of Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock worth $1,000,000 after buying an additional 102 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its position in shares of Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock valued at $485,000 after buying an additional 102 shares during the last quarter. M&T Bank Corp lifted its stake in shares of Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after buying an additional 108 shares in the last quarter. Finally, MGO One Seven LLC boosted its position in Zimmer Biomet by 5.1% during the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock worth $238,000 after acquiring an additional 110 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.39% of the company's stock.

Zimmer Biomet Stock Performance

Shares of ZBH traded up $2.05 during midday trading on Wednesday, reaching $94.32. 2,662,430 shares of the stock were exchanged, compared to its average volume of 1,700,857. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.92 and a twelve month high of $122.25. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The company has a market capitalization of $18.66 billion, a price-to-earnings ratio of 21.20, a PEG ratio of 1.95 and a beta of 0.78. The business's 50-day moving average price is $104.81 and its 200 day moving average price is $106.24.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm's revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.94 earnings per share. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.02%. Zimmer Biomet's payout ratio is 21.24%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Truist Financial set a $101.00 target price on Zimmer Biomet in a report on Tuesday. Robert W. Baird cut their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday. Wells Fargo & Company decreased their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday. The Goldman Sachs Group decreased their target price on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research report on Tuesday. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $114.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.